All patients
age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) beta variant (B.1.351 / 501Y.V2, South Africa) delta variant (B.1.617.2, Indian) elderly (typically over 65yr) positive for SARS-Cov-2 at baseline
Non replicating viral vector in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.20 [0.02; 1.72]
ENSEMBLE (COV3001), 0 0.19 [0.04; 0.81]
0.19 [0.06 ; 0.64 ] ChAdOx1 phase 3 (AstraZeneca), 2020, ENSEMBLE (COV3001), 0 2 0% 55,419 moderate not evaluable hospitalizationdetailed results ENSEMBLE (COV3001), 0 0.18 [0.03; 1.17]
0.18 [0.03 ; 1.17 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable symptomatic Covid-19detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.26; 0.43]
ENSEMBLE (COV3001), 0 0.33 [0.27; 0.41]
0.33 [0.28 ; 0.39 ] ChAdOx1 phase 3 (AstraZeneca), 2020, ENSEMBLE (COV3001), 0 2 0% 56,235 moderate not evaluable asymptomatic COVID casedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.23; 0.48]
0.33 [0.23 ; 0.48 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable infection (PCR positive symptomatic or not)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.44 [0.33; 0.59]
0.44 [0.33 ; 0.59 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable severe COVID-19 occurrencedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54]
ENSEMBLE (COV3001), 0 0.23 [0.11; 0.48]
0.24 [0.12 ; 0.48 ] ChAdOx1 phase 3 (AstraZeneca), 2020, ENSEMBLE (COV3001), 0 2 0% 62,803 moderate not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.24 [0.14; 0.41]
0.24 [0.14 ; 0.41 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 18,494 NA not evaluable serious adverse eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.86 [0.64; 1.17]
0.86 [0.64 ; 1.17 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable ATE (Myocardial infarction or ischemic stroke)detailed results ENSEMBLE (COV3001), 0 0.50 [0.12; 2.00]
0.50 [0.12 ; 2.00 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable deep vein thrombosisdetailed results ENSEMBLE (COV3001), 0 3.00 [0.61; 14.86]
3.00 [0.61 ; 14.86 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable Guillain-Barré syndrome detailed results ENSEMBLE (COV3001), 0 1.00 [0.06; 15.98]
1.00 [0.06 ; 15.98 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable ischemic strokedetailed results ENSEMBLE (COV3001), 0 0.67 [0.11; 3.99]
0.67 [0.11 ; 3.99 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable Myocardial infarction detailed results ENSEMBLE (COV3001), 0 1.00 [0.02; 50.39]
1.00 [0.02 ; 50.39 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable pericarditis detailed results ENSEMBLE (COV3001), 0 2.00 [0.07; 59.60]
2.00 [0.07 ; 59.60 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable pulmonary embolismdetailed results ENSEMBLE (COV3001), 0 4.00 [0.45; 35.79]
4.00 [0.45 ; 35.79 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable venous thromboembolism detailed results ENSEMBLE (COV3001), 0 2.75 [0.88; 8.64]
2.75 [0.88 ; 8.64 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results ENSEMBLE (COV3001), 0 2.00 [0.07; 59.60]
2.00 [0.07 ; 59.60 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable appendicitisdetailed results ENSEMBLE (COV3001), 0 1.20 [0.37; 3.93]
1.20 [0.37 ; 3.93 ] ENSEMBLE (COV3001), 0 1 0% 43,783 NA not evaluable Bell's palsydetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.20; 4.83]
ENSEMBLE (COV3001), 0 1.50 [0.25; 8.98]
1.18 [0.36 ; 3.89 ] ChAdOx1 phase 3 (AstraZeneca), 2020, ENSEMBLE (COV3001), 0 2 0% 67,528 moderate not evaluable immediate allergic reactiondetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15]
1.95 [0.07 ; 58.15 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable multiple sclerosisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15]
1.95 [0.07 ; 58.15 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable myelitisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.18; 21.52]
1.95 [0.18 ; 21.52 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Gastrointestinal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.03; 3.13]
0.33 [0.03 ; 3.13 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Musculoskeletal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.06; 15.60]
0.98 [0.06 ; 15.60 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Neuroinflammatory disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.22 [0.33; 4.54]
1.22 [0.33 ; 4.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Skin disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.73 [0.16; 3.27]
0.73 [0.16 ; 3.27 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Vasculitidesdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54]
0.49 [0.02 ; 14.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Thromboembolic eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.15; 1.62]
0.49 [0.15 ; 1.62 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-04 22:15 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 821,1288,1287,1286,760,1284,802,765,1285,759
- roots T: 290
